

**Key points.....** 9**HIV and AIDS.....** 12

<b>1.1. Number of people living with HIV/AIDS. Magnitude and impact of HIV .....</b>	13
1.1.1. Diagnosed and undiagnosed HIV-infected people (global prevalence estimations).....	13
1.1.2. Prevalence of HIV in key populations .....	14
1.1.3. HIV incidence.....	17
1.1.4. Life expectancy, survival and causes of mortality .....	17
1.1.5. Projections .....	18
<b>1.2. HIV/AIDS diagnosis .....</b>	18
1.2.1. HIV diagnoses.....	18
1.2.2. Late diagnoses.....	20
1.2.3. AIDS diagnoses .....	20
1.2.4. HIV infection/AIDS in Barcelona .....	21
<b>1.3. HIV and hepatitis C virus co-infection .....</b>	22
1.3.1. The hepatitis C virus: general situation .....	22
1.3.2. Number of people living with HIV and HCV co-infection .....	23
1.3.3. Prevalence of HCV in key populations of people with HIV .....	24
1.3.4. HCV incidence .....	25
1.3.5. HCV treatment .....	25
1.3.6. Progression and mortality .....	26
1.3.7. Behaviours associated with HIV and HCV co-infection in MSM.....	26
<b>1.4. HIV screening test .....</b>	28
1.4.1. Number of HIV diagnostic tests.....	28
1.4.2. Characteristics of the people who request the HIV test and of the positive cases detected in the alternative centres where the test is offered.....	30
1.4.3. Coverage of the HIV test in groups with high-risk behaviours .....	32
1.4.4. HCV and HIV rapid test pilot study in harm reduction centres .....	33
1.4.5. Rapid HIV test pilot study in Emergency Room .....	34
<b>1.5. Chemoprophylaxis and treatment of HIV.....</b>	36
1.5.1. Treatment of HIV infection .....	36
1.5.2. Service cascade.....	36
1.5.3. Mother-to-child transmission .....	37
1.5.4. Pre-exposure prophylaxis. Knowledge, attitudes and behaviours .....	37

**Other sexually transmitted infections .....** 38

<b>2.1 Infectious and congenital syphilis .....</b>	39
2.1.1. New diagnosis.....	39
2.1.2. Laboratory notification.....	41
<b>2.2 Neisseria gonorrhoeae .....</b>	40
2.2.1. New diagnosis .....	40
2.2.2. Laboratory notification .....	41
2.2.3. Surveillance of antibiotic sensitivity .....	41
2.2.4. Prevalence.....	42
<b>2.3 Genital infection due to Chlamydia trachomatis L1-L3: Lymphogranuloma venereum .....</b>	42
2.3.1. New diagnosis .....	42
<b>2.4 Genital infection due to Chlamydia trachomatis D-K serovars .....</b>	43
2.4.1. New diagnosis .....	43
2.4.2. Laboratory notification .....	44
2.4.3. Prevalence.....	44
<b>2.5 Infection by the genital Herpes Simplex virus .....</b>	45
2.5.1. New diagnosis .....	45

2.5.2.    Laboratory notification .....	46
<b>2.6 Infection by human papillomavirus: condyloma acuminata or anogenital wart .....</b>	<b>46</b>
2.6.1.    New diagnoses .....	46
<b>2.7 Infection due to Trichomonas vaginalis .....</b>	<b>47</b>
2.7.1.    New diagnosis .....	47
2.7.2.    Laboratory notification .....	48
<b>2.8 Hepatitis C .....</b>	<b>48</b>
 <b>Monitoring of HIV/STIs-associated behaviours.....</b>	 <b>50</b>
<b>3.1. Men who have sex with men.....</b>	<b>51</b>
<b>3.2. Female sex workers.....</b>	<b>52</b>
<b>3.3. People who inject drugs.....</b>	<b>53</b>
<b>3.4. Young People.....</b>	<b>54</b>
3.4.1.    Young People and the Internet .....	54
3.4.2.    Young attendees of ASSIR and youth care centres .....	55
3.4.3.    Young people in prison .....	56
<b>3.5. Acceptability of the new technologies to notify an STI/HIV to sexual partners of MSM.....</b>	<b>57</b>
 <b>Indicators for the surveillance and evaluation of HIV/STI infection<sup>59</sup></b>	 
 <b>Sources of information .....</b>	 <b>90</b>
 <b>Annexes .....</b>	 <b>101</b>
I) <b>Provisional data about new HIV diagnoses and AIDS cases reported in 2014 in Catalonia</b>	<b>102</b>
II) <b>Ten global indicators in HIV monitoring .....</b>	<b>104</b>
III) <b>Abbreviations .....</b>	<b>105</b>
IV) <b>Collaborators from contributing information systems .....</b>	<b>106</b>
V) <b>Relevant publications since 2012.....</b>	<b>112</b>